Changes in Roche Board of Directors
Basel, 05 December 2016
At its December meeting, the Board of Directors (BoD) of Roche Holding decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 14 March 2017. Professor Pius Baschera, a member of the BoD since 2007, has decided not to stand for re-election at the AGM in 2017 following 10 years of tenure. The BoD proposes Anita Hauser, Vice-Chairwoman of the Board of Directors of Bucher Industries AG, for election to the BoD at the 2017 AGM.
“As a member of the Board and of the Corporate Governance and Sustainability Committee, Pius Baschera has made significant contributions to Roche’s success,” said Roche Chairman Christoph Franz. “On behalf of the Roche Board of Directors, I would like to extend our sincerest thanks to him.” Christoph Franz added: “I am delighted with our nomination of Anita Hauser for election as a new member of the Board. She is a successful Swiss business leader with extensive experience in a globally operating family company and a strong marketing and sales skills set.”
The following current members of the BoD are recommended for re-election:
|Name||Board member since|
|Dr Christoph Franz (as Chairman)||2011|
|Professor Sir John Irving Bell||2001|
|Professor Dr Richard P. Lifton||2015|
|Dr Andreas Oeri||1996|
|Dr Claudia Suessmuth Dyckerhoff||2016|
|Dr Severin Schwan||2013|
|Peter R. Voser||2011|
Anita Hauser’s CV: http://www.roche.com/cv_anita_hauser.pdf
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best possible way.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.